Introduction
Primary hyperoxaluria (PH) is a rare inherited metabolic disease. In Type 1 (PH1), where the liver-specific peroxisomal enzyme alanine:glyoxylate aminotransferase (AGT) [1] is deficient or mistargeted to mitochondria, first presentation varies from occasional stone passage at an adult age to end-stage renal disease (ESRD) with multiorgan failure before the first year of life. Glyoxylate is converted into oxalate and glycolate instead of glycine, causing increased endogenous oxalate production and renal excretion. Urolithiasis and nephrocalcinosis, due to oxalate precipitating with calcium as insoluble crystals, lead to interstitial nephritis, fibrosis and ultimately renal insufficiency. Renal insufficiency impairs oxalate excretion, resulting in systemic oxalosis with oxalate deposition predominantly in bone, skin, retina, myocardium, vessel walls and the central nervous system [2] [3] [4] [23] [24] .
The AGTX gene encodes the AGT enzyme. Over 150 AGXT mutations have been identified in PH1, segregating the major or minor haplotype. The minor haplotype, occurring in 20% of Western populations, is defined by the appearance of several polymorphic variants. Some AGXT gene mutations act in synergy with these polymorphisms, and would not be pathognomonic otherwise [5, 6, [21] [22] . Mutation analysis serves as the most accurate and noninvasive diagnostic test. The p.Gly170Arg and p.Phe152Ile genotypes predict a favourable response to pharmacological dosages of pyridoxine, with a decline in urinary oxalate up to normal levels. Pyridoxine is metabolized in the body to pyridoxal phosphate, the main co-factor of AGT [6] [7] [8] .
The heterogeneous clinical appearance may explain frequent delay in establishing the diagnosis [3, [9] [10] [11] [12] . Classically, childhood onset of symptoms was regarded to be predictive of early ESRD. Adult presentation was considered mild, with occasional stone passage and preservation of renal function [3, 10, 13] . Contrary to this, in our previous cohort study of PH1 patients in the Netherlands, we were confronted with several cases of ESRD in adults caused by undiagnosed PH1 [12] . This was remarkable in view of the high number of patients homozygous for the favourable p.Gly170Arg or p.Phe152Ile genotype [8] .
In this follow-up cohort study [12] , we aim to (i) confirm the high number and relatively poor outcome of patients diagnosed at an adult age, (ii) investigate the possibility to preserve renal function if therapy is started early and (iii) assess pyridoxine-responsive and -unresponsive genotypes in relation to renal and patient survival.
Materials and methods

Sources
The survey is a cohort study of all known Dutch PH1 patients, assembled from (i) all previously diagnosed patients [12] as retrieved by a nationwide search among ( paediatric) nephrologists in 2000; (ii) a new search by mail among all members of the Dutch Federation of Nephrology. Non-responders were approached personally by S.v.d.H. or C.S.v.W.; (iii) patients diagnosed in the Dutch Hyperoxaluria Centre, Amsterdam, the Dutch reference centre for molecular and enzyme diagnostics in PH1 and (iv) an additional search by the national Dutch Registry of patients on renal replacement therapy (RENINE, Rotterdam, The Netherlands). The registration at RENINE is a prerequisite for reimbursement of dialysis costs.
Data collection
Clinical, genetic and biochemical data were obtained by reviewing medical charts after informed consent was signed by the patient.
Analysis
The diagnosis of PH1 was defined by (i) deficient AGT activity in a liver biopsy specimen [1] , (ii) mutations in the AGTX gene that have been linked to the disease in previous reports as demonstrated by mutation analysis [6, 8] , (iii) hyperoxaluria and hyperglycolic aciduria (values exceeding 0.5 mmol/L oxalate or 0.054 mmol oxalate/ mmol creatinine and 0.14 mmol glycolate/mmol creatinine), (iv) hyperoxaluria, if diagnosis was confirmed in family members and (v) highly suspicious circumstantial evidence; with severe systemic oxalosis, oxalate crystal deposition in renal transplant with elevated oxalate and glycolate serum levels [12] .
Therapeutic delay was the time between first symptoms and diagnosis, time of follow-up was the time between diagnosis and last clinical investigation or death. The paediatric age was defined <18 years and an adult age ≥18 years. Pyridoxine responsiveness was determined as a decline in the urinary or plasma oxalate levels of >30% (dosage 400-1200 mg/day).
Preserved renal function was defined as an estimated glomerular filtration rate (eGFR) >60 mL/min/1.73 m 2 , renal insufficiency as eGFR <60 mL/min/1.73 m 2 and ESRD as being dependent on chronic renal replacement therapy. Death due to PH1 was considered in oxalosisrelated problems, such as cardiac failure because of cardiac calcium oxalate crystal deposition, vascular complications or complication from dialysis or transplantation procedures.
For genotype-phenotype correlations, we used results of DNA analysis in patients and their siblings. For prognostic analysis, three categorical variables were created: (i) homozygous pyridoxine-responsive genotype, p.Gly170Arg and p.Phe152Ile, (ii) heterozygous pyridoxine-responsive genotype and (iii) all other genotypes. The primary outcome measure was renal function (dichotomized by defining the preserved renal function and favourable prognosis opposed to ESRD and poor prognosis) and patient survival. The secondary outcome was therapeutic delay. Patients, diagnosed by family screening, were analysed separately for outcome. Statistical package used was PASW statistics 18. The results were expressed as the median and range for continues variables and percentages for categorical variables. Cumulative survivals for kidney and patients were analysed using the KaplanMeier method with cases stratified according to genotype as classified above. The Cox regression model was used for comparison between subgroups (Figure 1 ).
Results
Population
Out of the 218 physicians approached, the response rate was 91%. We included 22 new PH1 patients, of whom 5 diagnosed before and 17 after 2000. Overall, we collected 79 PH1 patients from 61 different families diagnosed in the Netherlands over a period of 56 years (Table 1 ). One out of 57 patients included in 2000 was lost to follow-up. Mutation analysis performed in 61 patients showed 118 out of 122 expected mutated alleles ( Table 2 ). Because of the low numbers of patients with PH Type 2 (n = 3) as well as undifferentiated PH (n = 1), these were excluded from analysis.
Clinical characteristics and renal involvement at the time of diagnosis
Urolithiasis, nephrocalcinosis or both were reported at the time of diagnosis in 64 patients (81%). Of the 15 remaining patients, the presenting symptoms in 8 patients were related to ESRD (fatigue, anaemia, etc.) and 7 were diagnosed after family screening including 1 with failure to thrive and renal insufficiency at 3 months of age. In three of the eight patients with ESRD-related symptoms, diagnosis was before the age of 6 months, one at the age of 10 years and four at an adult age. All except one had symptoms of systemic oxalosis.
For the entire cohort, 13 patients (16%) presented symptoms before the age of 1 year. Eight of these infantile hyperoxaluria patients had signs of ESRD as presenting symptom. Of all 17 new patients diagnosed after 2000, 52% was diagnosed at an adult age and 8 (48%) in ESRD of whom 6 with systemic oxalosis.
In adult age-diagnosed patients, 62% had reached renal insufficiency and 52% ESRD at the time of diagnosis, compared with 42% with renal insufficiency and 26% in ESRD for paediatric-diagnosed patients. In 10 of the 29 adult-diagnosed patients, first manifestation of disease was at paediatric age (median: 8.8, range: 2-18 years), 5 of them (50%) reached ESRD before diagnosis was established.
Patient survival
The cumulative patient survival was 95, 80 and 72% at 10, 30 and 50 years of age, respectively. Twenty-one patients died due to PH1 or its treatment. Eighteen (86%) had reached ESRD, three died of complications after liver transplantation and one after acute on chronic renal failure Number of patients/number of patients for whom the information could be obtained. 
Number of patients (including siblings). b One patient with compound heterozygous Phe152Ile, GLy170Arg_ Val336Asp.
due to urolithiasis. One patient died due to a metastatic mammary carcinoma (Table 3) .
Renal survival
Of the 37 patients with a preserved renal function at the time of diagnosis, 10 (27%) developed renal insufficiency of whom six reached ESRD after a median follow-up of 21 years (range: 12-37). Four of 10 (40%) patients with the preserved renal function diagnosed at an adult age developed ESRD-three of them having a pyridoxine-responsive genotype and receiving pyridoxine-compared with 2/27 (7%) patients with a preserved renal function diagnosed at the paediatric age. In these subgroups, renal insufficiency was observed in 0/10 versus 4/27 (15%) patients.
Early detection by family screening
Of the sixteen patients diagnosed through family screening (Table 4) , 13 had preserved renal function. During the median follow-up of 20 (range: 10.9-37.3) years only one patient, homozygous for the p.Gly170Arg genotype, developed a decline in renal function. Hyperoxaluria was detected but this patient was lost to follow-up and treatment was delayed by 9.3 years until the development of ESRD. One patient with a decline in renal function died after seven years of follow-up at the age of 13 because of liver failure after pre-emptive liver transplantation. Another patient died at the age of 83.8 years due to acuteon chronic renal failure as a consequence of urolithiasis obstruction.
Genotype and outcome: homozygosity for pyridoxineresponsive genotypes p.Gly170Arg or p.Phe152Ile (Table 5) Fifteen of the 25 (60%) patients homozygous for a pyridoxine-responsive genotype (15 p.Gly170Arg and 10 p.Phe152Ile) were diagnosed at an adult age and six (24%) after family screening. Eleven (eight with the p. Gly170Arg genotype) presented with a decline in renal function of whom eight (six with the p.Gly170Arg genotype) had reached ESRD. In 64% of the 14 patients with a preserved renal function at diagnosis (five diagnosed by family screening) and were receiving pyridoxine during follow-up, renal function was preserved after a median follow-up of 16 (range:
Three of the 15 (20%) patients heterozygous for the pyridoxine-responsive genotype were diagnosed at an adult age. Seven out of eight clinically tested patients were responsive to pyridoxine. All eight patients with a preserved renal function at the time of diagnosis also had a preserved renal function after a median follow-up of 14 years (range: 2-28). One patient had a decline in renal function at the time of diagnosis but improved and reached normal GFR at time of follow-up.
Other genotypes
In 21 patients, four diagnosed at an adult age and six by family screening, another genotype was found (Table 2) . Of nine patients presenting with a preserved renal function, eight had a preserved renal function during the follow-up of 20 (range: 1-34) years. Five patients died, three with c.33dupC and two with p.Gly170Arg_ Val336Asp genotypes. One patient (homozygous p.Ile244Thr) was responsive to pyridoxine. All six patients with the c.33dupC mutation developed symptoms and were diagnosed before the age of 7 months, four in ESRD. Two others had a preserved renal function through the entire follow-up. For the patients with the p. Gly170Arg_Val336Asp genotype, the median therapeutic delay was 10 years with first symptoms at a median of 5 and diagnosis at a median of 22 years. Two presented with ESRD, reaching ESRD at an age of 22 and 27 years, respectively. 
Post-transplantation diagnosis
Five patients were diagnosed after renal transplantation, and one patient was diagnosed only after a second renal transplantation. The median age at first symptoms was 24 (range: 2-45) and 46 (range: 31-54) years at diagnosis. ESRD occurred at a median age of 41 (range: 28-53) years. The median delay was 25 (range: 4-49) years. Three patients were homozygous and one was heterozygous for a pyridoxine-responsive genotype. Two patients were successfully renal transplanted after the diagnosis was made.
One patient subsequently underwent a combined liverkidney transplantation followed by transplant failure (native liver still in situ). Three patients died at the ages of 32, 55 and 63 years. All three suffered from systemic oxalosis involving bones and hearth.
Discussion
According to our study, the estimated prevalence of PH1 in the Netherlands is the highest as compared with other cohort studies in Western countries, reflecting an underdetection of the disease in these countries [10, [14] [15] [16] . Our results confirm a high prevalence of ESRD at the time of diagnosis in the entire population but again, as compared with our previous cohort study [12] , predominantly in adult-diagnosed patients.
To the best of our knowledge this is the only cohort study that systematically searched for PH1 patients in both paediatric and adult populations. As a consequence we found the highest number of adult-diagnosed patients (38%) as compared with other studies. Kopp et al. [14] found 6/25 (24%) patients with age at diagnosis >14 years in Switzerland and Harambat et al. [10] found 21% of patients diagnosed at an adult age. Only Takayama et al. [17] reported higher rates with 49% of 59 Japanese patients being over 20 years of age at the time of diagnosis in a cohort consisting of previously published cases and patients known from personal communication.
The high prevalence of ESRD as a presenting sign of the disease contradict the assumption of a favourable prognosis in patients with the so-called 'adult onset of disease', previously described as a late-onset form with occasionally stone passage [18] . This has been confirmed by Harambat et al. [10] who found ESRD as the presenting symptom in 60% of patients diagnosed at an adult age and Takayama et al. [17] who found 93% ESRD in Japanese patients aged over 20 years at the time of diagnosis. However, from the study of Harambat et al. [10, 17] the overall prevalence of PH1 is much lower than in our study. Yet, the low number of patients and the used methodology makes it impossible to estimate the real prevalence and age distribution of PH1 in Japan.
Of all adult age diagnosed patients with ESRD, over 30% had symptoms since childhood. In five, PH1 was diagnosed only after renal transplantation. These findings imply a systematic underdetection of PH1. Moreover, the occurrence of renal involvement even in patients diagnosed though family screening shows that adequate metabolic screening is often delayed.
The lack of metabolic screening in adult patients with stone disease also explains in part the relative high proportion of ESRD at diagnosis in adult age-diagnosed patients in the French, Japanese as well as in our study. As Beck and Hoppe [19] pointed out, adult patients may be diagnosed and treated for ESRD of unknown origin without any further investigation. Thus, the screening for metabolic disorders in all patients with unexplained ESRD or recurrent urolithiasis may lead to a higher prevalence of PH1, including milder phenotypes.
Three findings illustrate the importance of early diagnosis and start of treatment. First, the vast majority of patients diagnosed through family screening preserved or prevented decline in renal function despite development of ESRD in the majority of the index cases. The occurrence of ESRD in one, despite a favourable genotype (p.Gly170Arg), could be explained by therapeutic delay due to loss of follow-up. Remarkably, even in patients without response to pyridoxine therapy, kidney function was preserved. This finding is not biased by a shorter period of follow-up in screened patients. Secondly, a high prevalence of pyridoxine-responsive genotypes in this cohort provides an excellent opportunity for successful conservative treatment by declining endogenous oxalate production. Paradoxically, in this subgroup a large observed therapeutic delay had resulted in the development of ESRD, which could have been easily prevented by pyridoxine treatment. Thirdly, a surprising favourable prognosis was observed in patients with other genotypes and preserved renal function at the time of diagnosis. There was no difference in follow-up duration explaining this. Conservative treatment may preserve renal function in these patients, which is highly important as offering liver transplantation can result in early death as shown in our study. Therefore, the timing of diagnosis seems of utmost importance to improve the outcome in PH1 patients. This is in line with the studies of Fargue et al. [20] and Lieske et al [15] who found late diagnosis to be associated with an adverse outcome. In addition to a favourable outcome in early-diagnosed patients, outcome may hypothetically be influenced by environmental differences, yet be identified as modifier genes, transport properties of the SLC26A6 transporter and Oxalobacter formigenes colonization [3] .
Recurrent urolithiasis or nephrocalcinosis was the presenting symptom in 81% of the patients comparable to findings of others [10, 14, 16, 20] . Therefore, clinical signs of stone disease or unexplained renal insufficiency should imply metabolic work-up to exclude a treatable metabolic disorder like PH1.
The mortality rate (28%) was comparable to results of Kopp et al. [14] (28%) and higher than the rate found by Harambat et al. [10] (13%). A high number of adultdiagnosed patients who had higher mortality rates compared with the others may explain this. The survival difference could not be attributed to difference in the follow-up time, as this was longest in the paediatric group. On the contrary, the higher mortality rate among adult diagnosed patients is best explained by longer kidney exposure to oxalate due to longer therapeutic delay. This leads to higher prevalence of renal insufficiency or ESRD at the time of diagnosis, with dialysis, transplantation or systemic oxalosis-related mortality. We believe this is an underestimation, as historical data in the cohort lack reports of oxalosis in autopsies.
Genotype-phenotype relationships
We found patients with a homozygous pyridoxine-sensitive genotype developing ESRD at much higher age than patients with other mutations. Higher levels of residual activity of AGT in homozygous and heterozygous p.Gly170Arg and p.Phe152Ile patients probably results in lower endogenous oxalate production and less kidney damage [10] . However, this does not prevent the development of kidney damage after long-term exposure in untreated patients. As in our cohort, therapeutic delay was the longest in homozygous p.Gly170Arg and p.Phe152Ile patients, the occurrence of ESRD might have been prevented by earlier diagnosis. This is especially important in view of the extremely high prevalence of the potentially most easily treatable pyridoxine-responsive genotypes in the Dutch cohort. Pyridoxine-responsiveness was clinically also proven in heterozygous p.Gly170Arg and p.Phe152Ile patients which should be a motivational tool for treatment compliance in patients. Interestingly, we found one patient being homozygous for the p.Ile244Thr genotype responsive to pyridoxine. This observation, which was previously made in France (oral communication, J. Harambat), suggests that this genotype is pyridoxine responsive. This should be explored in more detail in other cohorts as well. Our findings contrast with the French cohort study, in which less ESRD was found in patients with pyridoxine responsive-associated mutations. The overall longer follow-up of our study and the larger number of adult age diagnosed, pyridoxine-sensitive Dutch PH1 patients explains this difference [10] .
Limitations of our study are inherent to its retrospective nature. Ascertainment bias may in part explain the high prevalence of ESRD as we systematically approached nephrologists but not urologists. Another potential source for bias is the selection of patients for genotype studies. Patients, who died before molecular analyses could be performed, may bias the results toward the milder spectrum. Therefore, the percentage of patients (66%) who respond to pyridoxine treatment as predicted by genotype (41% homozygous, 25% heterozygous) may be lower than estimated in the current population.
Conclusions
PH1 is too often missed in patients with recurrent stone disease or sibs with PH1 and may consequently lead to a high rate of diagnosis in ESRD at an adult age. This predominantly occurs in patients with pyridoxine-responsive genotypes, who are relatively easy to treat with conservative measures. Yet, an early diagnostic screening preserves renal function in all patients, even in those with pyridoxine-unresponsive mutations. Our findings warrant improvement of awareness among physicians with further implementation of diagnostic screening for PH1 in patients with recurrent urolithiasis or unexplained renal insufficiency. A timely start of conservative treatment could preserve renal function in the long term.
